6/7/2010

Spain's Grifols plans to acquire Talecris Biotherapeutics, a manufacturer of plasma-based treatments, for about $3.4 billion. The agreement comes a year after Australia's CSL withdrew its $3.1 billion bid because of antitrust issues.

Related Summaries